Type of information: Production agreement
Company: Sun Pharmaceutical Industries (India) Samsung BioLogics (Republic of Korea)
Type agreement: manufacturing - bioproduction
Details: • On July 4, 2017, Sun Pharmaceutical Industries and Samsung BioLogics announced a strategic long-term manufacturing agreement for tildrakizumab. The agreement was entered into by Sun Pharma’s wholly-owned subsidiary and Samsung BioLogics. According to the agreement, Sun Pharma has appointed Samsung BioLogics to manufacture this investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.
Financial terms: The approximate value of the contract will be US$ 55.5 million, other financial details of the agreement are confidential.